Premium
Atrophic areas and/with neovascular AMD. Characteristics, evolution of atrophic lesions associated to neovascular AMD treated by series of 3 Ranibizumab IVT protocol, 4 years follow‐up
Author(s) -
GONZALEZ C
Publication year - 2012
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2012.2717.x
Subject(s) - ranibizumab , medicine , macular degeneration , ophthalmology , surgery , chemotherapy , bevacizumab
Purpose To evaluate atrophic areas characteristics, at the first time, their change, evolution and correlation or no with and during the follow‐up of neovascular AMD treatment by series of 3 Ranibizumab IVT Methods 102 eyes of 91 patients, 28 men, 63 women, with retrofoveolar neovascularisation complicating AMD. Atrophic areas were evaluated by autofluorescence imaging Spectralis (in particular with region finder software), OCT (notably choriocapillary depth), FA, ICG. We evaluate the size, characteristics, topography of the lesions, their growth way. The areas themselves, their edge and rim were considered and evaluated. Each element was studied, compared cut to cut and time to time to itself and to each other data, every 2 months. The impact of AMD and /or this treatment protocol on the evolution of atrophic areas is also valuate. Results VA improved in 85% cases, stabilized in 15%. AF imaging and their region finder analyze were the main elements of the atrophic lesions’ study. The surface of the atrophic area grows by 17%, the edge changes in 20%. Speed growth was in average 1,15mm2/year. At OCT, thickness of photoreceptor, pigment epithelium layer diminished about 25% and 35% at the area’s edge. Choriocapillary depth values, FA and ICG data were mainly significative in the large atrophic areas and less than AF indications. This protocol has a little impact on the evolution of atrophic areas, apparently less than monthly IVT, and the same as AMD by itself. Conclusion The study of atrophic process and its progression is a main question in the AMD follow –up, the evaluation of the protocol treatments and their safety too.